| 26.315 0.205 (0.79%) | 11-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.27 | 1-year : | 38.86 |
| Resists | First : | 28.48 | Second : | 33.27 |
| Pivot price | 21.48  |
|||
| Supports | First : | 15.19 | Second : | 6.98 |
| MAs | MA(5) : | 26.53 |
MA(20) : | 18.17 |
| MA(100) : | 9.11 |
MA(250) : | 6.07 |
|
| MACD | MACD : | 4.5 |
Signal : | 3.8 |
| %K %D | K(14,3) : | 89.6  |
D(3) : | 93.7 |
| RSI | RSI(14): 84.2 |
|||
| 52-week | High : | 28.48 | Low : | 1.86 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TERN ] has closed below upper band by 20.0%. Bollinger Bands are 314.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 26.52 - 26.65 | 26.65 - 26.79 |
| Low: | 25.01 - 25.14 | 25.14 - 25.28 |
| Close: | 26.1 - 26.31 | 26.31 - 26.53 |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Sun, 23 Nov 2025
BMO Believes Market Undervalues Terns Pharmaceuticals (TERN) Despite Strong Trial Data - Yahoo Finance UK
Fri, 21 Nov 2025
First Week of July 2026 Options Trading For Terns Pharmaceuticals (TERN) - Nasdaq
Wed, 19 Nov 2025
Terns Pharma (TERN) Sees Target Price Raised by Truist Securities | TERN Stock News - GuruFocus
Wed, 19 Nov 2025
Could Positive Early Data for TERN-701 Shift Terns Pharmaceuticals' (TERN) Long-Term Competitive Position? - Yahoo Finance
Tue, 18 Nov 2025
Commit To Buy Terns Pharmaceuticals At $20, Earn 36.5% Annualized Using Options - Nasdaq
Tue, 18 Nov 2025
Terns Pharmaceuticals (TERN) Soars to New Record High of $26.12 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 90 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 97.4 (%) |
| Shares Short | 10,690 (K) |
| Shares Short P.Month | 8,230 (K) |
| EPS | -1.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20 % |
| Return on Equity (ttm) | -29.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -25.8 |
| PEG Ratio | 0 |
| Price to Book value | 8.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -30.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|